Exxon Q4 2025 Earnings Beat Estimates

Exxon Q4 2025 earnings beat consensus with $1.71 EPS and strong cash flow from lower-cost Permian and Guyana production reinforcing investor confidence.

January 30, 2026·2 min read
View all news articles
Flat-vector oil pump and pipeline representing Exxon Q4 2025 earnings beat and cash-flow strength from Permian and Guyana.

KEY TAKEAWAYS

  • Q4 non-GAAP EPS was $1.71, beating $1.68 consensus and revenue topped $82.3 billion.
  • Operating cash flow was $12.7 billion and free cash flow was $5.6 billion.
  • Lower-cost Permian and Guyana production improved unit economics and underpinned funding for growth to 2030.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Exxon Mobil reported Q4 2025 results on Jan. 30, 2026, with earnings beating estimates as lower-cost production in the Permian Basin and Guyana offset crude-price headwinds and supported strong cash flow.

Q4 Results and Cash Flow

The company said in a press release on Jan. 30, 2026, that it posted non-GAAP earnings of $1.71 a share for the quarter, beating the $1.68 consensus by $0.03. Revenue reached $82.3 billion, surpassing the $81.0 billion forecast. Operating cash flow totaled $12.7 billion, while free cash flow was $5.6 billion. GAAP net income for the quarter was $6.5 billion, and earnings excluding items came to $7.3 billion.

For full-year 2025, GAAP net income declined to $28.8 billion from $33.7 billion in 2024. Non-GAAP earnings excluding items fell to $30.1 billion from $33.5 billion, with full-year non-GAAP EPS at $6.99 compared with $7.79 the prior year.

Production Drivers and Outlook

Exxon attributed the quarter’s outperformance to lower-cost oil production in the Permian Basin and Guyana, which improved unit economics and value capture per barrel and molecule. CEO Darren Woods said, "We're capturing more value from every barrel and molecule we produce and building growth platforms at scale, creating a long runway of profitable growth through 2030 and beyond."

The earnings beat came despite crude oil posting its largest annual price decline since 2020 in 2024. Shares traded near record highs ahead of the report, even as analysts trimmed profit forecasts.

Exxon’s strong cash generation combined with lower-cost barrels provides operating leverage to fund scaled investment and growth platforms toward 2030.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Netflix Earnings Send NFLX Stock Lower

Netflix Earnings Send NFLX Stock Lower

Netflix earnings for Q1 2026 beat forecasts but weak Q2 guidance and Reed Hastings' planned June exit pushed shares lower in after-hours trading.

Anthropic Mythos Rolls Out to Banks Amid Cyber Scrutiny

Anthropic Mythos Rolls Out to Banks Amid Cyber Scrutiny

Anthropic Mythos limited Glasswing rollout to banks prompted regulator scrutiny and raised cyber and operational risk, complicating bank positioning.

Spirit Airlines Liquidation Looms as Fuel Costs Surge

Spirit Airlines Liquidation Looms as Fuel Costs Surge

Spirit Airlines liquidation risk rises as jet fuel may exceed year-end cash, prompting creditors' doubts and forcing traders to reassess credit exposure.

AMD Stock Rises on Bernstein Raise and AI Demand

AMD Stock Rises on Bernstein Raise and AI Demand

AMD stock rose after Bernstein raised its 12-month target as record EPYC and MI300 data-center demand boosted flows ahead of May 5 Q1 2026 earnings.

Anthropic Claude Opus 4.7 Launches to General Availability

Anthropic Claude Opus 4.7 Launches to General Availability

Anthropic Claude Opus 4.7 went general; pricing stayed unchanged and Mythos stayed gated, a setup that could shift cloud AI costs and investor positioning.

Abbott Earnings Beat After Exact Sciences Deal

Abbott Earnings Beat After Exact Sciences Deal

Abbott earnings posted revenue and adjusted-profit beats but narrowed FY EPS guidance after the Exact Sciences acquisition, likely pressuring shares.